ReviewFrontiers in immunology2013
TWEAK: A New Player in Obesity and Diabetes.
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Association between targeted inflammatory proteomics and insulin sensitivity as well as beta-cell function in subjects with normal glucose tolerance.Journal of molecular cell biology · 2026Article
- Integrative proteomic analysis provides novel therapeutic insights for etiological subtypes of diabetes.Diabetes, obesity & metabolism · 2025Article
- Article
- Association between weight-adjusted-waist index and retinopathy among American adults: a cross-sectional study and mediation analysis.Frontiers in nutrition · 2025Article
- Inflammation and Neurodegeneration in Glaucoma: Isolated Eye Disease or a Part of a Systemic Disorder? - Serum Proteomic Analysis.Journal of inflammation research · 2024Article
- TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse.Molecular cancer research : MCR · 2023Article
- Exercise Improves Clinical Symptoms, Pathological Changes and Oxidative/Antioxidative Balance in Animal Model of Colitis.International journal of preventive medicine · 2023Article
- The TWEAK/Fn14/CD163 axis-implications for metabolic disease.Reviews in endocrine & metabolic disorders · 2022Review
- Limited extent and consequences of pancreatic SARS-CoV-2 infection.Cell reports · 2022Article
- New Insights in Cytokines in Childhood Obesity: Changes in TWEAK and CD163 After a 2-Year Intervention Program in Prepubertal Children With Obesity.Frontiers in endocrinology · 2022Article
- Circulating sTweak is associated with visceral adiposity and severity in patients with obstructive sleep apnea syndrome.Scientific reports · 2021Article
- Article
- TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?Clinical science (London, England : 1979) · 2019Review
- Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance.PloS one · 2019Article
- Multi-omic analysis of signalling factors in inflammatory comorbidities.BMC bioinformatics · 2018Article
- Overexpressing STAMP2 attenuates adipose tissue angiogenesis and insulin resistance in diabetic ApoEJournal of cellular and molecular medicine · 2017Article
- Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia.World journal of diabetes · 2017Review
- Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.HIV clinical trials · 2017Article
- Article
- Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15-34 years of age: a prospective cohort study.Diabetology & metabolic syndrome · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and type 2 diabetes (T2D) are associated with chronic low-grade inflammation. Mounting evidence suggests the involvement of an inflammatory switch in adipose tissue, both in mature adipocytes and immune-competent cells from the stromal vascular compartment, in the progression of obesity and insulin resistance. Several inflammatory cytokines secreted by obese adipose tissue, including TNFα and IL-6 have been described as hallmark molecules involved in this process, impairing insulin signaling in insulin-responsive organs. An increasing number of new molecules affecting the local and systemic inflammatory imbalance in obesity and T2D have been identified. In this complex condition, some molecules may exhibit opposing actions, depending on the cell type and on systemic or local influences. Tumor necrosis factor weak inducer of apoptosis (TWEAK), a cytokine of the tumor necrosis (TNF) superfamily, is gaining attention as an important player in chronic inflammatory diseases. TWEAK can exist as a full-length membrane-associated (mTWEAK) form and as a soluble (sTWEAK) form and, by acting through its cognate receptor Fn14, can control many cellular activities including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. Notably, sTWEAK has been proposed as a biomarker of cardiovascular diseases. Here, we will review the recent findings relating to TWEAK and its receptor within the context of obesity and the associated disorder T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.